Infinity Flicks is Pioneering the Future of Entertainment with AI-Generated Movies and Shows

Infinity Flicks, an innovative digital streaming platform, has launched its unique service offering AI-generated movies and shows. Founded by Joshua Darrington, a former top ChatGPT coach, the company leverages advanced AI technology to allow users to influence and personalize their viewing experience.

United States – Infinity Flicks, a trailblazer in the realm of digital streaming, proudly announces the launch of its innovative platform for AI-generated movies and shows. Founded by Joshua Darrington, a visionary and former top ChatGPT coach, Infinity Flicks represents a groundbreaking shift in entertainment, blending advanced AI technology with the art of storytelling.

Infinity Flicks stands out from conventional streaming services by utilizing cutting-edge AI to craft unique, AI-generated content. This technology empowers users to influence the creation process, offering a personalized viewing experience tailored to individual preferences. The platform boasts an extensive range of genres and themes, ensuring a rich and diverse content library that caters to all tastes.

“At Infinityflicks, we’re not just streaming movies; we’re creating a new frontier in entertainment where AI meets human imagination, crafting stories that resonate with each viewer uniquely,” says Joshua Darrington, Founder of Infinity Flicks. “Our vision at Infinityflicks is to revolutionize the way people consume movies, leveraging the power of AI to offer an unparalleled, personalized cinematic journey.”

Committed to ethical standards, Infinity Flicks ensures the responsible use of AI in content creation, prioritizing data privacy and user safety. The platform actively incorporates user feedback, constantly evolving to meet and exceed viewer expectations.

Infinity Flicks is proud to collaborate with leading AI filmmakers, including Aze Alter, Nice Aunties, Animals Eating Animals, and Ai.ded.it, fostering a community of innovation and creativity.

Founded on the belief that AI can transform the entertainment industry, Infinity Flicks is rapidly growing, with ambitions to become one of the leading digital platforms of the future. Darrington’s passion for AI and movies has been the driving force behind the company’s success, marking a pivotal moment in the evolution of entertainment.

For more information about Infinity Flicks and to experience the future of cinema, visit https://infinityflicks.com/.

Infinity Flicks, founded by Joshua Darrington, emerged from a deep passion for AI and its potential in movie production. Darrington, leveraging his expertise as the former #1 ChatGPT coach, saw the opportunity to revolutionize storytelling through AI technology. The platform’s rapid growth and innovative approach position it as a potential leader in the future of entertainment.

Media Contact
Company Name: Infinity Flicks
Contact Person: Joshua Darrington
Email: Send Email
Country: United States
Website: https://infinityflicks.com/

Dry Eye Disease Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | AbbVie, Allergan, AFT Pharma, Akorn, Alcon, Bausch Health, J&J

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Dry Eye Disease pipeline constitutes 45+ key companies continuously working towards developing 50+ Dry Eye Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Dry Eye Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Dry Eye Disease Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dry Eye Disease Market.

 

Some of the key takeaways from the Dry Eye Disease Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Dry Eye Disease treatment therapies with a considerable amount of success over the years. 
  • Dry Eye Disease companies working in the treatment market are Quorum Innovations, Serentrix, IVIEW Therapeutics, Taejoon Pharmaceutical, Seinda Pharmaceutical, Invirsa, GL Pharm Tech Corporation, Dreamhawk Vision Biotech, Inc, Aramis Biosciences, Kowa Company, Alcon, HanAll Biopharma, Seikagaku Corporation, Novaliq GmbH, and others, are developing therapies for the Dry Eye Disease treatment 
  • Emerging Dry Eye Disease therapies in the different phases of clinical trials are- Qi 401, SER-114, iVIEW 1001, TJO-083, SY-201, INV-102, GLH8NDE, SHJ 002, A197, K-161, AR-15512, HL036, SI-614, NOV03, CyclASol, and others are expected to have a significant impact on the Dry Eye Disease market in the coming years.   
  • In February 2023, “Novaliq revealed intentions to submit a Marketing Authorization Application (MAA) for CyclASol (ciclosporin ophthalmic solution), an innovative anti-inflammatory remedy aimed at addressing dry eye disease (DED) within the European Union.”
  • In November 2022, “Alcon declared the successful finalization of its acquisition of Aerie Pharmaceuticals. This acquisition has broadened Alcon’s portfolio with commercial products including netarsudil and latanoprost ophthalmic solution (Rocklatan) 0.02%/0.005% and netarsudil ophthalmic solution (Rhopressa) 0.02%, alongside AR-15512, a Phase 3 product in development for treating dry eye disease.”
  • In October 2022, “Aldeyra Therapeutics, Inc. concluded the phase 3 clinical study involving 0.25% reproxalap ophthalmic solution, an experimental medication under investigation for allergic conjunctivitis treatment. The company showcased the trial’s clinical findings at the American Academy of Optometry’s 2022 Annual Meeting.”
  • In October 2022, “Novaliq revealed that the U.S. Food and Drug Administration (FDA) had approved the New Drug Application (NDA) for CyclASol® (cyclosporine ophthalmic solution), an innovative anti-inflammatory remedy specifically designed to address the signs and symptoms of dry eye disease (DED). In the United States, the FDA has established a Prescription Drug User Fee Act (PDUFA) target action date for the CyclASol® New Drug Application (NDA).”
  • In November 2022, “Aerie Pharmaceuticals commenced a year-long, multicenter, double-masked, randomized Phase 3 trial, conducted at around 10 locations across the United States. All participants included in the study will be diagnosed with dry eye disease (DED). The trial will involve visits at Baseline (Day 1) as well as on Day 14, Day 90, Day 180, Day 270, and Day 365 (Study Exit).”
  • In January 2022, “NovaBay Pharmaceuticals introduced Avenova lubricating eye drops designed to address symptoms associated with dry eyes.”

 

Dry Eye Disease Overview

A lack of tear film homeostasis is the cause of dry eye disease (DED), also referred to as dry eye syndrome (DES), keratoconjunctivitis sicca (KCS), and keratitis sicca. DED is a multifactorial illness of the ocular surface.

 

Get a Free Sample PDF Report to know more about Dry Eye Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/dry-eye-disease-pipeline-insight

 

Emerging Dry Eye Disease Drugs Under Different Phases of Clinical Development Include:

  • Qi 401: Quorum Innovations
  • SER-114: Serentrix
  • iVIEW 1001: IVIEW Therapeutics
  • TJO-083: Taejoon Pharmaceutical
  • SY-201: Seinda Pharmaceutical
  • INV-102: Invirsa
  • GLH8NDE: GL Pharm Tech Corporation
  • SHJ 002: Dreamhawk Vision Biotech, Inc
  • A197: Aramis Biosciences
  • K-161: Kowa Company
  • AR-15512: Alcon
  • HL036: HanAll Biopharma
  • SI-614: Seikagaku Corporation
  • NOV03: Novaliq GmbH
  • CyclASol: Novaliq GmbH

 

Dry Eye Disease Route of Administration

Dry Eye Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Dry Eye Disease Molecule Type

Dry Eye Disease Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Dry Eye Disease Pipeline Therapeutics Assessment

  • Dry Eye Disease Assessment by Product Type
  • Dry Eye Disease By Stage and Product Type
  • Dry Eye Disease Assessment by Route of Administration
  • Dry Eye Disease By Stage and Route of Administration
  • Dry Eye Disease Assessment by Molecule Type
  • Dry Eye Disease by Stage and Molecule Type

 

DelveInsight’s Dry Eye Disease Report covers around 50+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Dry Eye Disease product details are provided in the report. Download the Dry Eye Disease pipeline report to learn more about the emerging Dry Eye Disease therapies

 

Some of the key companies in the Dry Eye Disease Therapeutics Market include:

Key companies developing therapies for Dry Eye Disease are – AbbVie Inc. (Allergan PLC), AFT Pharmaceuticals, Akorn, Alcon Inc., Bausch Health Companies Inc., Horus Pharma, Johnson & Johnson, Mitotech, Novaliq GmbH, OASIS Medical, Otsuka Pharmaceutical Co. Ltd, Prestige Consumer Healthcare, Santen Pharmaceutical Co. Ltd, Sentiss Pharma Pvt. Ltd, Sun Pharmaceutical Industries Ltd, VISUfarma, and others.

 

Dry Eye Disease Pipeline Analysis:

The Dry Eye Disease pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Dry Eye Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dry Eye Disease Treatment.
  • Dry Eye Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Dry Eye Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dry Eye Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Dry Eye Disease drugs and therapies

 

Dry Eye Disease Pipeline Market Drivers

  • Rise in geriatric population, increasing Exposure to computer screens, increased R&D Activities, adoption of new Technologies are some of the important factors that are fueling the Dry Eye Disease Market.

 

Dry Eye Disease Pipeline Market Barriers

  • However, lack of awareness about dry eye disease in low income countries, complexity of the disease, challenges associated with the Ocular drug delivery and other factors are creating obstacles in the Dry Eye Disease Market growth.

 

Scope of Dry Eye Disease Pipeline Drug Insight    

  • Coverage: Global
  • Key Dry Eye Disease Companies: Quorum Innovations, Serentrix, IVIEW Therapeutics, Taejoon Pharmaceutical, Seinda Pharmaceutical, Invirsa, GL Pharm Tech Corporation, Dreamhawk Vision Biotech, Inc, Aramis Biosciences, Kowa Company, Alcon, HanAll Biopharma, Seikagaku Corporation, Novaliq GmbH, and others
  • Key Dry Eye Disease Therapies: Qi 401, SER-114, iVIEW 1001, TJO-083, SY-201, INV-102, GLH8NDE, SHJ 002, A197, K-161, AR-15512, HL036, SI-614, NOV03, CyclASol, and others
  • Dry Eye Disease Therapeutic Assessment: Dry Eye Disease current marketed and Dry Eye Disease emerging therapies
  • Dry Eye Disease Market Dynamics: Dry Eye Disease market drivers and Dry Eye Disease market barriers 

 

Request for Sample PDF Report for Dry Eye Disease Pipeline Assessment and clinical trials

 

Table of Contents

1. Dry Eye Disease Report Introduction

2. Dry Eye Disease Executive Summary

3. Dry Eye Disease Overview

4. Dry Eye Disease- Analytical Perspective In-depth Commercial Assessment

5. Dry Eye Disease Pipeline Therapeutics

6. Dry Eye Disease Late Stage Products (Phase II/III)

7. Dry Eye Disease Mid Stage Products (Phase II)

8. Dry Eye Disease Early Stage Products (Phase I)

9. Dry Eye Disease Preclinical Stage Products

10. Dry Eye Disease Therapeutics Assessment

11. Dry Eye Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Dry Eye Disease Key Companies

14. Dry Eye Disease Key Products

15. Dry Eye Disease Unmet Needs

16 . Dry Eye Disease Market Drivers and Barriers

17. Dry Eye Disease Future Perspectives and Conclusion

18. Dry Eye Disease Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dry Eye Disease Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | AbbVie, Allergan, AFT Pharma, Akorn, Alcon, Bausch Health, J&J

Focal Segmental Glomerulosclerosis Pipeline Analysis, 2023 Updates | Latest FDA, EMA, and PMDA Approvals | B. Braun Melsungen, Beckman Coulter, Baxter International, ChemoCentryx, Complexa, Dimerix

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Focal Segmental Glomerulosclerosis pipeline constitutes 15+ key companies continuously working towards developing 18+ Focal Segmental Glomerulosclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Focal Segmental Glomerulosclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Focal Segmental Glomerulosclerosis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Focal Segmental Glomerulosclerosis Market.

 

Some of the key takeaways from the Focal Segmental Glomerulosclerosis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Focal Segmental Glomerulosclerosis treatment therapies with a considerable amount of success over the years. 
  • Focal Segmental Glomerulosclerosis companies working in the treatment market are Ceptur Therapeutics, Evergreen Therapeutics, Delta4, Certa Therapeutics, Boehringer Ingelheim, River 3 Renal Corp, Dimerix Bioscience, Travere Therapeutics, Inc., and others, are developing therapies for the Focal Segmental Glomerulosclerosis treatment 
  • Emerging Focal Segmental Glomerulosclerosis therapies in the different phases of clinical trials are- Research programme Oligonucleotides, EG-102, D4-101-02, OCX-063, BI764198, R3R 01, DMX-200, Sparsentan, and others are expected to have a significant impact on the Focal Segmental Glomerulosclerosis market in the coming years.   
  • In August 2022, The company finished its scheduled Type A meeting with the FDA regarding a potential submission seeking accelerated approval for sparsentan to treat FSGS. The FDA suggested that the study’s design in the DUPLEX Study retained the possibility for complete approval, contingent on the study’s completion, and advised the company to pursue standard approval based on the two-year eGFR slope.
  • In February 2022, Goldfinch Bio revealed encouraging initial findings from a phase 2 clinical study assessing gfb-887 as a personalized medicine for individuals diagnosed with focal segmental glomerulosclerosis (FSGS).
  • In September 2021, Vifor Pharma and Travere Therapeutics have entered a collaborative licensing agreement to market and distribute sparsentan across Europe, Australia, and New Zealand. Sparsentan is developed for the treatment of FSGS and IgAN, rare kidney diseases known for their progressive nature, often leading to end-stage kidney disease more frequently than other conditions.

 

Focal Segmental Glomerulosclerosis Overview

The hallmark of focal and segmental obliteration of glomerular capillary tufts inside enlarged matrix is known as focal segmental glomerular sclerosis (FSGS). FSGS is categorized based on the location and nature of the sclerotic lesion into collapsing, tip, cellular, perihilar, and not otherwise defined forms.

 

Get a Free Sample PDF Report to know more about Focal Segmental Glomerulosclerosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight

 

Emerging Focal Segmental Glomerulosclerosis Drugs Under Different Phases of Clinical Development Include:

  • Research programme Oligonucleotides: Ceptur Therapeutics
  • EG-102: Evergreen Therapeutics
  • D4-101-02: Delta4
  • OCX-063: Certa Therapeutics
  • BI764198: Boehringer Ingelheim
  • R3R 01: River 3 Renal Corp
  • DMX-200: Dimerix Bioscience
  • Sparsentan: Travere Therapeutics, Inc.

 

Focal Segmental Glomerulosclerosis Route of Administration

Focal Segmental Glomerulosclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Intravenous
  • Subcutaneous
  • Intramuscular

 

Focal Segmental Glomerulosclerosis Molecule Type

Focal Segmental Glomerulosclerosis Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide

 

Focal Segmental Glomerulosclerosis Pipeline Therapeutics Assessment

  • Focal Segmental Glomerulosclerosis Assessment by Product Type
  • Focal Segmental Glomerulosclerosis By Stage and Product Type
  • Focal Segmental Glomerulosclerosis Assessment by Route of Administration
  • Focal Segmental Glomerulosclerosis By Stage and Route of Administration
  • Focal Segmental Glomerulosclerosis Assessment by Molecule Type
  • Focal Segmental Glomerulosclerosis by Stage and Molecule Type

 

DelveInsight’s Focal Segmental Glomerulosclerosis Report covers around 18+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Focal Segmental Glomerulosclerosis product details are provided in the report. Download the Focal Segmental Glomerulosclerosis pipeline report to learn more about the emerging Focal Segmental Glomerulosclerosis therapies

 

Some of the key companies in the Focal Segmental Glomerulosclerosis Therapeutics Market include:

Key companies developing therapies for Focal Segmental Glomerulosclerosis are – B. Braun Melsungen AG, Beckman Coulter Inc. (Danaher), Baxter International Inc., ChemoCentryx Inc., Complexa Inc., Dimerix Ltd, Medtronic PLC, Pfizer Inc., Retrophin Inc., Variant Pharmaceuticals Inc., and others.

 

Focal Segmental Glomerulosclerosis Pipeline Analysis:

The Focal Segmental Glomerulosclerosis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Focal Segmental Glomerulosclerosis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Focal Segmental Glomerulosclerosis Treatment.
  • Focal Segmental Glomerulosclerosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Focal Segmental Glomerulosclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Focal Segmental Glomerulosclerosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Focal Segmental Glomerulosclerosis drugs and therapies

 

Focal Segmental Glomerulosclerosis Pipeline Market Drivers

  • Surge of interest in developing new therapies for FSGS, renaissance in clinical research in nephrology are some of the important factors that are fueling the Focal Segmental Glomerulosclerosis Market.

 

Focal Segmental Glomerulosclerosis Pipeline Market Barriers

  • However, the etiology and pathogenesis of Focal Segmental Glomerulosclerosis are very complex, high cost associated with the disease and other factors are creating obstacles in the Focal Segmental Glomerulosclerosis Market growth.

 

Scope of Focal Segmental Glomerulosclerosis Pipeline Drug Insight    

  • Coverage: Global
  • Key Focal Segmental Glomerulosclerosis Companies: Ceptur Therapeutics, Evergreen Therapeutics, Delta4, Certa Therapeutics, Boehringer Ingelheim, River 3 Renal Corp, Dimerix Bioscience, Travere Therapeutics, Inc., and others
  • Key Focal Segmental Glomerulosclerosis Therapies: Research programme Oligonucleotides, EG-102, D4-101-02, OCX-063, BI764198, R3R 01, DMX-200, Sparsentan, and others
  • Focal Segmental Glomerulosclerosis Therapeutic Assessment: Focal Segmental Glomerulosclerosis current marketed and Focal Segmental Glomerulosclerosis emerging therapies
  • Focal Segmental Glomerulosclerosis Market Dynamics: Focal Segmental Glomerulosclerosis market drivers and Focal Segmental Glomerulosclerosis market barriers 

 

Request for Sample PDF Report for Focal Segmental Glomerulosclerosis Pipeline Assessment and clinical trials

 

Table of Contents

1. Focal Segmental Glomerulosclerosis Report Introduction

2. Focal Segmental Glomerulosclerosis Executive Summary

3. Focal Segmental Glomerulosclerosis Overview

4. Focal Segmental Glomerulosclerosis- Analytical Perspective In-depth Commercial Assessment

5. Focal Segmental Glomerulosclerosis Pipeline Therapeutics

6. Focal Segmental Glomerulosclerosis Late Stage Products (Phase II/III)

7. Focal Segmental Glomerulosclerosis Mid Stage Products (Phase II)

8. Focal Segmental Glomerulosclerosis Early Stage Products (Phase I)

9. Focal Segmental Glomerulosclerosis Preclinical Stage Products

10. Focal Segmental Glomerulosclerosis Therapeutics Assessment

11. Focal Segmental Glomerulosclerosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Focal Segmental Glomerulosclerosis Key Companies

14. Focal Segmental Glomerulosclerosis Key Products

15. Focal Segmental Glomerulosclerosis Unmet Needs

16 . Focal Segmental Glomerulosclerosis Market Drivers and Barriers

17. Focal Segmental Glomerulosclerosis Future Perspectives and Conclusion

18. Focal Segmental Glomerulosclerosis Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Focal Segmental Glomerulosclerosis Pipeline Analysis, 2023 Updates | Latest FDA, EMA, and PMDA Approvals | B. Braun Melsungen, Beckman Coulter, Baxter International, ChemoCentryx, Complexa, Dimerix

We Are Love by Yvonne O’Halloran is an Enchanting Children’s Book that Teaches Readers about the True Purpose of Life

Yvonne O’ Halloran’s We Are Love is a whimsical children’s book that takes readers on an enchanting adventure through a magical forest, unveiling profound answers about who we truly are and why we are here.

Yvonne O’Halloran is the author of empowering children’s books including Plant-Powered Animal Protectors and We Are Love. Through her works, she is committed to educating children about essential subjects including love, empathy, unity, nutrition and equality.

Yvonne is also the founder of Living Vegan and an Accredited Practicing Dietitian. She has a Masters in Nutrition & Dietetics and a flourishing online business where she helps clients achieve better health and vitality through diet and lifestyle changes.

Yvonne is originally from Ireland where she met her husband Daniel and is a vegan mum to three beautiful children who she is homeschooling. Yvonne and her family live on the Gold Coast in Australia.

This one-on-one interview shares Yvonne O’ Halloran’s background and experience in writing We Are Love.

Tell us about We Are Love.

In We Are Love, two fairies named Poppy and Fern embark on a magical quest to meet a mighty wizard. Along their journey, they encounter a host of fascinating fairy folk and creatures, each offering their unique perspective on the meaning of life.

The story emphasizes kindness and respect towards others, promoting unity and understanding. It is designed to teach young readers the significance of fostering harmonious relationships with others and creating a better world. Overall, We Are Love is a heart-warming tale that encourages children to embrace these virtues and highlights the transformative impact they can have on individuals and communities. With its engaging plotline, memorable characters and meaningful morals, this book is sure to captivate young readers leaving a positive and lasting impression.

What inspired you to write We Are Love?

The inspiration for We Are Love came from my youngest daughter, who at just three years old, expressed a profound understanding of love itself. One day she said “Mommy, did you know that we are love?” Her innocent and heartfelt words generated a creative spark within me. As I reflected on her words, a rhyming story began to form in my mind, and I felt compelled to write it down immediately, even pulling over my car to capture the inspiration.

When prompted on why she thought to say that, her response was “because my heart told me to.” Therefore, I feel that this book was supposed to be created so that this special message could be shared.

Personally, I am passionate about helping children remember that we are all connected and the ultimate goal of the book is to help unify future generations and to bring humanity together by creating positive change.

How did your background and experience influence your writing?

I am passionate about educating children, especially around the topics of spirituality and plant-based nutrition. I have been a writer for nearly a decade now, first starting by blogging, then writing content for companies, websites, and magazine publications, and finally onto both fiction and non-fiction books. I am a plant-based dietitian, passionate about topics that center around holistic nutrition, compassion, love, equality, respect and the interconnectedness of body, mind, and spirit.

Over the past 3-4 years, I personally have gone on a spiritual journey and awakened to the fact that separation is an illusion and the truth is that we are all connected, and our souls are pure, unconditional love. If we can connect with our heart and remember who we really are and why we are all here, I believe we possess the capacity to shape the world’s path towards a much brighter future. What better way to do this than to educate and inspire future generations!

What is one message you would like readers to remember?

I want readers to know that they are more powerful and special than they realize, and everything they need is within them.

Remember to love yourself first, as the power of love and positivity can take you a long way in this human life, leaving a lasting impression on others you come into contact with.

Every single child was sent here at this time to fulfill an important mission in helping humanity evolve and remember who they are.

So, let’s fill the world with high vibration energy while helping others along the way!

Purchasing the Book

With a powerful message distilled into an accessible, profound, and engaging book, Yvonne presents a revolutionary way of unveiling one’s inner self to inspire the next generation to live a life of joy, purpose and impact.

The book is available for sale on Amazon, Barnes & Noble, Apple iBooks, Nook, and other online bookstores.

Whether you are searching for the perfect birthday present, a heartfelt Christmas gift, or a special surprise for your child, grandchild, or a niece or nephew, We Are Love is a cherished keepsake that will bring joy and inspiration to young minds. Give the gift of wonder and adventure with a book that will be treasured for years to come: https://www.amazon.com.au/We-Are-Love-Yvonne-Halloran/dp/064527643X/

Connect with Yvonne O’ Halloran

www.yvonneohalloran.com

https://www.linkedin.com/in/yvonne-o-halloran-â“¥-a03219173

https://www.instagram.com/yvonne_plantbaseddietitian/

https://www.facebook.com/livingvegandietitian

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: We Are Love by Yvonne O’Halloran is an Enchanting Children’s Book that Teaches Readers about the True Purpose of Life

Time Passages Announces Definitive Journey Biography: Journey: Worlds Apart

New book delivers a comprehensive exploration of the multi-platinum band Journey.

Time Passages announces JOURNEY: WORLDS APART, the definitive accounting of the “Don’t Stop Believin’” hitmakers by award-winning journalist Nick DeRiso. A multiple columnist of the year award-winner with the USA Today network, DeRiso conducted dozens of interviews to compile a book that’s not just a biography of Journey – it’s a backstage pass. 

Journey started as a dream for former Santana road manager Herbie Herbert, who thought he could build a blockbuster band out of the remnants of post-Woodstock Santana with Gregg Rolie and Neal Schon. Turns out, he could – but it would take a few albums, and the arrival of frontman Steve Perry. By the time Rolie exited at the turn of the ‘80s, Journey was already a multi-platinum band – and they would only get bigger with the addition of Jonathan Cain from Journey’s former opening act, The Babys.

Solo projects and long periods apart slowed their momentum until Perry finally left for good in the late ‘90s. Then Journey was faced with one of its biggest challenges: Whether and how to move forward without the singer who had redefined their sound forever on songs like “Open Arms,” “Only the Young” and “When You Love a Woman.”

The story is guided from their earliest roots by conversations with co-founding members Schon, Rolie and Prairie Prince, along with long-time Herbert confidant Pat Morrow. DeRiso then follows Journey toward pop-culture superstardom through additional talks with later-era collaborators Cain, Steve Smith, Deen Castronovo, Steve Augeri and scores of producers, sidemen, label representatives and acknowledged experts like former Rolling Stone contributing editor David Wild, original MTV VJ Martha Quinn, and longtime San Francisco Chronicle music writer Joel Selvin, the latter of whom covered Journey almost from the beginning.

Along the way, JOURNEY: WORLDS APART emerges as the definitive look back at Journey, with deep explorations of every era, every album and every song. Pathway collaborations and key side projects complete this detailed analysis, as DeRiso speaks with John Waite, Jan Hammer, Marco Mendoza, Ron Wikso and others.

NICK DeRISO is assistant managing editor with Townsquare Media. TIME PASSAGES most recently published EAGLES: UP AHEAD IN THE DISTANCE, the second in a three-book series. 

Media Contact
Company Name: Time Passages
Contact Person: Rik Forgo
Email: Send Email
Country: United States
Website: http://timepassages.net

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Time Passages Announces Definitive Journey Biography: Journey: Worlds Apart

ESR1-mutated Metastatic Breast Cancer Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Eisai, Roche, AstraZeneca, Sun Pharma, Arvinas

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, ESR1-mutated Metastatic Breast Cancer pipeline constitutes key companies continuously working towards developing ESR1-mutated Metastatic Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The ESR1-mutated Metastatic Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“ESR1-mutated Metastatic Breast Cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the ESR1-mutated Metastatic Breast Cancer Market.

 

Some of the key takeaways from the ESR1-mutated Metastatic Breast Cancer Pipeline Report:

  • Companies across the globe are diligently working toward developing novel ESR1-mutated Metastatic Breast Cancer treatment therapies with a considerable amount of success over the years. 
  • ESR1-mutated Metastatic Breast Cancer companies working in the treatment market are Sun Pharma, Eisai Co Ltd, Olema Pharmaceuticals, Sermonix Pharmaceuticals, AstraZeneca, Radius Pharmaceuticals, Berlin-Chemie (Menarini Group), Pfizer, G1 Therapeutics, Zenopharm, Arvinas, H3 Biomedicine, Eisai, Roche, Zentalis Pharmaceuticals, and others, are developing therapies for the ESR1-mutated Metastatic Breast Cancer treatment 
  • Emerging ESR1-mutated Metastatic Breast Cancer therapies in the different phases of clinical trials are- SCO-120, H3B-6545, OP1250, Lasofoxifene, Camizestrant (AZD9833), Elacestrant (RAD1901), Ibrance (Palbociclib), Rintodestrant (G1T48), ZB716, ARV-471, H3B-6545, Giredestrant (RG6171, GDC-9545), ZN-c5, and others are expected to have a significant impact on the ESR1-mutated Metastatic Breast Cancer market in the coming years.  
  • On August 17, 2022, “Sanofi halted the worldwide clinical development initiative for amcenestrant, an experimental oral selective estrogen receptor degrader (SERD).”
  • In August 2022, “Zentalis revealed the cessation of clinical development for ZN-c5, their oral SERD, and ZN-e4, an EGFR inhibitor. This decision was made after the completion of ongoing clinical trials in both programs, which are now closed for further participant enrollment.”
  • In August 2022, “The FDA has given priority review status to the New Drug Application (NDA) for elacestrant intended for treating patients diagnosed with estrogen receptor (ER)-positive/HER2-negative advanced or metastatic breast cancer. The regulatory agency is anticipated to make a decision on the application by February 17, 2023, in accordance with the Prescription Drug User Fee Act.”
  • In August 2022, “The FDA has awarded OP-1250 a fast-track designation for addressing patients diagnosed with ER-positive, HER2-negative metastatic breast cancer.”
  • In April 2022, Roche announced the first-quarter result and stated that giredestrant missed the mark in the Phase II acelERA trial in advanced breast cancer, the emerging oral selective estrogen receptor degrader (SERD) class.
  • On October 21, 2022, “Sermonix Pharmaceuticals Inc., a private biopharmaceutical firm dedicated to developing innovative treatments for ESR1-mutated metastatic breast and gynecological cancers, shared further results from its Phase II Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE 1) study at the 4th Annual Congress of the International Society of Liquid Biopsy (ISLB) in Miami.”

  

ESR1-mutated Metastatic Breast Cancer Overview

In essence, metastatic breast cancer is a kind of Stage IV breast cancer in which the cancer starts in the breast tissue and subsequently spreads to other places of the body. The majority of human breast cancers begin as estrogen-dependent tumors that express the estrogen receptor (ER), and the steroid hormone estradiol plays a critical role in the evolution of breast cancer.

 

Get a Free Sample PDF Report to know more about ESR1-mutated Metastatic Breast Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/esr1-mutated-metastatic-breast-cancer-pipeline-insight

 

Emerging ESR1-mutated Metastatic Breast Cancer Drugs Under Different Phases of Clinical Development Include:

  • SCO-120: Sun Pharma Advanced Research Company Ltd
  • H3B-6545: Eisai Co Ltd
  • OP1250: Olema Pharmaceuticals
  • Lasofoxifene: Sermonix Pharmaceuticals
  • Camizestrant (AZD9833): AstraZeneca
  • Elacestrant (RAD1901): Radius Pharmaceuticals/Berlin-Chemie (Menarini Group)
  • Ibrance (Palbociclib): Pfizer
  • Rintodestrant (G1T48): G1 Therapeutics, Inc.
  • ZB716: Zenopharm
  • ARV-471: Arvinas
  • H3B-6545: H3 Biomedicine/Eisai
  • Giredestrant (RG6171, GDC-9545): Roche
  • ZN-c5: Zentalis Pharmaceuticals

 

ESR1-mutated Metastatic Breast Cancer Route of Administration

ESR1-mutated Metastatic Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

ESR1-mutated Metastatic Breast Cancer Molecule Type

ESR1-mutated Metastatic Breast Cancer Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

ESR1-mutated Metastatic Breast Cancer Pipeline Therapeutics Assessment

  • ESR1-mutated Metastatic Breast Cancer Assessment by Product Type
  • ESR1-mutated Metastatic Breast Cancer By Stage and Product Type
  • ESR1-mutated Metastatic Breast Cancer Assessment by Route of Administration
  • ESR1-mutated Metastatic Breast Cancer By Stage and Route of Administration
  • ESR1-mutated Metastatic Breast Cancer Assessment by Molecule Type
  • ESR1-mutated Metastatic Breast Cancer by Stage and Molecule Type

 

DelveInsight’s ESR1-mutated Metastatic Breast Cancer Report covers around products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further ESR1-mutated Metastatic Breast Cancer product details are provided in the report. Download the ESR1-mutated Metastatic Breast Cancer pipeline report to learn more about the emerging ESR1-mutated Metastatic Breast Cancer therapies

 

Some of the key companies in the ESR1-mutated Metastatic Breast Cancer Therapeutics Market include:

Key companies developing therapies for ESR1-mutated Metastatic Breast Cancer are – Eisai, Roche, AstraZeneca, Sun Pharma, Zenopharm, Arvinas, Sermonix Pharmaceuticals, H3 Biomedicine, Radius Pharmaceuticals, Berlin-Chemie, Pfizer, G1 Therapeutics, Inc., Zentalis Pharmaceuticals, Olema Pharmaceuticals, and others.

 

ESR1-mutated Metastatic Breast Cancer Pipeline Analysis:

The ESR1-mutated Metastatic Breast Cancer pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of ESR1-mutated Metastatic Breast Cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ESR1-mutated Metastatic Breast Cancer Treatment.
  • ESR1-mutated Metastatic Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • ESR1-mutated Metastatic Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ESR1-mutated Metastatic Breast Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about ESR1-mutated Metastatic Breast Cancer drugs and therapies

 

ESR1-mutated Metastatic Breast Cancer Pipeline Market Drivers

  • Rise in global prevalence of ESR1 gene in Metastatic Cancer, increasing research and development activities, technological advancements are some of the important factors that are fueling the ESR1-mutated Metastatic Breast Cancer Market.

 

ESR1-mutated Metastatic Breast Cancer Pipeline Market Barriers

  • However, poor Understanding of the disease and its prognosis, lack of Efficient Diagnostic Tools and other factors are creating obstacles in the ESR1-mutated Metastatic Breast Cancer Market growth.

 

Scope of ESR1-mutated Metastatic Breast Cancer Pipeline Drug Insight    

  • Coverage: Global
  • Key ESR1-mutated Metastatic Breast Cancer Companies: Sun Pharma, Eisai Co Ltd, Olema Pharmaceuticals, Sermonix Pharmaceuticals, AstraZeneca, Radius Pharmaceuticals, Berlin-Chemie (Menarini Group), Pfizer, G1 Therapeutics, Zenopharm, Arvinas, H3 Biomedicine, Eisai, Roche, Zentalis Pharmaceuticals, and others
  • Key ESR1-mutated Metastatic Breast Cancer Therapies: SCO-120, H3B-6545, OP1250, Lasofoxifene, Camizestrant (AZD9833), Elacestrant (RAD1901), Ibrance (Palbociclib), Rintodestrant (G1T48), ZB716, ARV-471, H3B-6545, Giredestrant (RG6171, GDC-9545), ZN-c5, and others
  • ESR1-mutated Metastatic Breast Cancer Therapeutic Assessment: ESR1-mutated Metastatic Breast Cancer current marketed and ESR1-mutated Metastatic Breast Cancer emerging therapies
  • ESR1-mutated Metastatic Breast Cancer Market Dynamics: ESR1-mutated Metastatic Breast Cancer market drivers and ESR1-mutated Metastatic Breast Cancer market barriers 

 

Request for Sample PDF Report for ESR1-mutated Metastatic Breast Cancer Pipeline Assessment and clinical trials

 

Table of Contents

1. ESR1-mutated Metastatic Breast Cancer Report Introduction

2. ESR1-mutated Metastatic Breast Cancer Executive Summary

3. ESR1-mutated Metastatic Breast Cancer Overview

4. ESR1-mutated Metastatic Breast Cancer- Analytical Perspective In-depth Commercial Assessment

5. ESR1-mutated Metastatic Breast Cancer Pipeline Therapeutics

6. ESR1-mutated Metastatic Breast Cancer Late Stage Products (Phase II/III)

7. ESR1-mutated Metastatic Breast Cancer Mid Stage Products (Phase II)

8. ESR1-mutated Metastatic Breast Cancer Early Stage Products (Phase I)

9. ESR1-mutated Metastatic Breast Cancer Preclinical Stage Products

10. ESR1-mutated Metastatic Breast Cancer Therapeutics Assessment

11. ESR1-mutated Metastatic Breast Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. ESR1-mutated Metastatic Breast Cancer Key Companies

14. ESR1-mutated Metastatic Breast Cancer Key Products

15. ESR1-mutated Metastatic Breast Cancer Unmet Needs

16 . ESR1-mutated Metastatic Breast Cancer Market Drivers and Barriers

17. ESR1-mutated Metastatic Breast Cancer Future Perspectives and Conclusion

18. ESR1-mutated Metastatic Breast Cancer Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ESR1-mutated Metastatic Breast Cancer Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Eisai, Roche, AstraZeneca, Sun Pharma, Arvinas

Los Angeles Roof Replacement Company Fills Niche Market Need

Metal Roofing Los Angeles offers roof replacement and re-roofing services for commercial and residential properties. Most other roofers do not work with metal roofs; Metal Roofing does, and it is a specialty for the company.

Metal Roofing Los Angeles is pleased to announce that the company specializes in metal roof replacement and installation. The Los Angeles roof replacement company also works on other types of roofing installation. It is proud to be the recognized leader in the market niche as a service to commercial and residential customers throughout Los Angeles County and the nearby area. If the homeowner or business owner ultimately decides against metal, the licensed and experienced installers can still work on their roof; the team actually works on all types of roofing, including asphalt shingles, flat roofs, and tile roofs.

There are several reasons why homeowners are turning to metal roofs as their choice; some of the reasons include durability and sustainability. For commercial customers, a metal roof can protect against the climate. Metal roofs are very eco-friendly. The installation of a metal roof can also provide a stylish finish to the property. The company will help customers choose the right type of roofing for the structure. The professional team will also take the lead in installing the roof to avoid any inconvenience or damage in the future.

Additional details about their roof replacement services are available at https://www.metalroofinglosangeles.net/replacement/

Metal roofs guarantee long-lasting performance when compared to other materials. A metal roof is the best choice if a home or business owner is thinking about a roof replacement. The installers are trained and licensed in the roof installation work that they do. The company offers services to commercial and residential building owners who want a metal roofing system. Metal Roofing Los Angeles gives incomparable service and high-quality materials for all clients.

Metal roofs are growing in popularity in the Los Angeles metropolitan area. Apart from adding value to homes, metal roof is long-lasting and requires minimal maintenance. For homeowners who don’t have the luxury of time to check on their roof from time to time, this is a big help. Inspecting the roof twice annually will ensure that there are no issues. For eco-conscious individuals, metal roofs are recyclable. A panel made of roofing metal won’t end up in the landfill like other roofing materials.

For home or business owners who are planning to build or renovate their building, a metal roof should be an option. As Los Angeles has warm temperatures, higher cooling costs are expected, but installing a metal roofing system can help to lower costs. Metal roofs reflect the sun’s UV rays, which lessens the heat in the establishment. Metal roofs also do not require high maintenance. They are also durable, so repairing or replacing them will take a longer time. Metal roofs can make the property aesthetically pleasing by choosing the right color and style. Metal Roofing Los Angeles experts will help from start to finish by providing only trustworthy services.

Whether the metal roof is for a home or a commercial building, it is a good idea. A metal roof increases the property’s value in regard to aesthetics and robustness. Different styles include copper, steel, metal roof shingles or shakes, aluminum, galvalume roofs, metal tiles, sheet metal roofing, a standing seam metal roof, and many more. A metal roof installation can last as long as 40 or even 70 years, saving the customer a lot. There is no need to pay for a roof check-up because the roof only requires maintenance twice a year.

About the Company: 

Metal Roofing Los Angeles has the experience and training to install metal roofing systems. The company operates in LA County and nearby. Although the area of specialization is metal roofs, the company can also install other types of roofs. The firm handles roofing projects of all sizes.

Media Contact
Company Name: Metal Roofing Los Angeles
Contact Person: Irving Cannis
Email: Send Email
Phone: (323) 968-6348
Address:1225 Cypress Ave, Ste 3 #V119
City: Los Angeles
State: CA 90065
Country: United States
Website: https://www.metalroofinglosangeles.net/

Artillery Unveils Reliable Budeget Klipper 3D printer – Sidewinder X4 Pro

Established in China in 2018, Artillery is a brand dedicated to consumer-grade 3D printers. Following the success of its well-known 3D printers, Hornet, Genius, and Sidewinder X2 due to its technology innovation, Artillery now proudly announces its latest FDM 3D printer, the Sidewinder X4 Pro. 

The Sidewinder X4 Pro features a quiet Klipper motherboard and ARM 64-bit 1.5GHz quad-core high-performance processor, boasting a maximum print speed of up to 500mm/s and a top acceleration of 12000 mm/s².

Compared to its former printers, the X4 Pro comes with metal linear rails for the X & Y axis and a dual-pull-rod design. Leveraging the excellent rigidity and stability of linear rails effectively reduces system vibrations and noise. The dual-pull-rods, forming a stable triangular structure, prevent Z-axis vibrations, ensuring remarkable print quality even at high speeds.

Notably, the X4 Pro is equipped with an all-metal hotend with a large melting zone reaching 300°C. This enables the printer to handle strong and long filaments such as nylon, ABS, carbon fiber, ASA, PC, catering to diverse printing needs. The dual-gear, all-metal direct drive extruder enhances precision in filament extrusion, facilitating the printing of flexible and elastic materials with ease.

In addition, the X4 Pro features WiFi wireless functionality, enabling remote control and monitoring of the printing process with a one-click start.

With a print volume of 240X240X260mm, the X4 Pro boasts additional features such as 81-point auto-leveling, resume printing function, LED light kit, etc,.

The Sidewinder X4 Pro is competitively priced at $319 on the official Artillery store. Now subscribe to the official email for early bird discount notifications, early bird discount valid until December 10th. For more information,check out the Sidewinder X4 Pro on Artillery’s website.

Specifications

Media Contact
Company Name: Shenzhen Yuntu Chuangzhi Technology Co., Ltd.
Contact Person: Gong Lei
Email: Send Email
Country: China
Website: https://www.artillery3d.com/pages/artillery-sidewinder-x4-pro

Discover the Art of Independent Cinema at the Greenville Independent Film Festival

The Greenville Independent Film Festival (GIFF), founded by the visionary Gregory Bazile, invites cinema enthusiasts and the general public to its annual celebration of independent filmmaking. On December 10, 2023, from 2:00 PM to 7:00 PM, the Camelot Theater (48 East Antrim Dr., Greenville, SC 29607) will be transformed into a vibrant hub of artistic expression, showcasing a diverse range of independent films.

Gregory Bazile’s life story, marked by remarkable achievements in filmmaking, entrepreneurship, and beyond, sets the tone for an event celebrating creativity and resilience. From his humble beginnings in the Louisiana Bayous to his creative explorations in New York City, Gregory’s journey epitomizes the spirit of the independent filmmaker – fearless, innovative, and ever-evolving.

The Greenville Independent Film Festival is not just an event; it’s a movement. It stands as a testament to the power of independent cinema, offering a unique platform for emerging filmmakers and seasoned veterans alike. This year’s festival promises an eclectic mix of films, including thought-provoking documentaries, avant-garde shorts, and narrative features that challenge the status quo.

GIFF’s mission is to foster a community where independent filmmakers can thrive, share their stories, and connect with audiences who appreciate the unadulterated essence of indie cinema. The festival aims to ignite conversations, spark new ideas, and create a space where cinema is not just watched but experienced.

Attendees can look forward to a day filled with inspiring film screenings, engaging panel discussions, and networking opportunities with industry professionals. The festival also provides a platform for filmmakers to present their work to a discerning audience, offering valuable feedback and the chance to gain recognition in the independent film community.

This year’s festival lineup reflects GIFF’s commitment to diversity and inclusivity, featuring works that span various genres, cultures, and perspectives. From the raw and unfiltered to the whimsical and profound, every film promises to be a window into the world of its creator.

The Greenville Independent Film Festival is a celebration of the unbridled creativity that drives independent cinema. It’s an opportunity for film enthusiasts to discover new voices, for filmmakers to showcase their talent, and for the community to come together in appreciation of the art form.

We invite you to join us at the Camelot Theater on December 10th to experience the magic of independent cinema. Whether you’re a film aficionado, a budding filmmaker, or someone who simply loves good movies, the Greenville Independent Film Festival is the place to be.

Embrace the opportunity to immerse yourself in the world of independent film, where each screening is not just a presentation but a journey into the heart and soul of storytelling.

Welcome to the Greenville Independent Film Festival – Your Gateway to the World of Independent Cinema! For more information, visit: www.greenvilleindependentfilmfestival.org

Media Contact
Company Name: Rachel Dares PR
Contact Person: RACHEL B DARES
Email: Send Email
Phone: 7147189043
Address:16480 Bake Parkway
City: Irvine
State: CA
Country: United States
Website: www.RachelDaresPR.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Discover the Art of Independent Cinema at the Greenville Independent Film Festival

Leveraging Technology for Leadership Development: Dee Agarwal’s Digital Approaches

Dee Agarwal, a C-suite business leader, advocates for leveraging technology, including virtual leadership workshops, online mentorship platforms, AI-powered feedback systems, and more to transform leadership development in response to the challenges of the remote work era.

ATLANTA, GA – December 7, 2023 – The integration of technology has become pivotal in shaping the leaders of tomorrow, especially in the context of the evolving work landscape. Deepak (Dee) Agarwal, an experienced C-suite business leader, has been at the forefront of this transformation, recognizing the imperative to adapt leadership and development skills to a more virtual environment in the era of remote work. In response to this shift, he suggests strategically employing innovative digital approaches to not only navigate the challenges posed by remote work but also to enhance leadership skills and foster professional growth amongst his teams. We’ll explore how Dee Agarwal leverages technology to cultivate effective leadership in the dynamic realm of virtual collaboration and remote team management.

1. Virtual Leadership Workshops:

Dee Agarwal recognizes the imperative of virtual leadership workshops in today’s fast-paced business landscape. In a world driven by digital connectivity, leaders must adeptly navigate virtual communication. Virtual leadership workshops, distinct from traditional in-person sessions, leverage online platforms to provide a collaborative space for executives to refine their communication skills. Dee Agarwal emphasized, “In this dynamic environment, virtual workshops become essential, offering our executives the opportunity to adapt their leadership styles to the nuances of digital interaction. These workshops serve as a crucial space for leaders to sharpen their abilities in team collaboration, conflict resolution, and strategic thinking—skills vital in the contemporary business environment, where effective leadership extends beyond physical boundaries.”

2. Online Mentorship Platforms:

Deepak also places a premium on mentorship as a cornerstone of leadership growth. He noted, “Mentorship is not limited by geographical boundaries. Through online mentorship platforms, emerging leaders can be connected with seasoned mentors globally, fostering a diverse and enriching learning experience.” By leveraging these platforms, Agarwal believes that leaders can gain insights from various perspectives, contributing to a more well-rounded leadership style.

3. Gamification for Skill Enhancement:

According to Investopedia, gamification leverages the psychological principles that make games engaging to tap into people’s intrinsic motivation and create a more immersive and enjoyable experience in non-game contexts. In Dee Agarwal‘s leadership strategy, gamification plays a pivotal role in skill enhancement. “Leadership is not just about theoretical knowledge; it’s about practical application. Gamification allows our executives to engage in simulations of real-world scenarios, making the learning experience both immersive and memorable,” Dee Agarwal asserted. By turning leadership development into more than conferences and conversations, participants can develop and apply skills in a risk-free environment, enhancing their ability to make strategic decisions in the boardroom. The value of gamification lies in its capacity to create an interactive and dynamic learning atmosphere, fostering a sense of competitiveness and collaboration among participants, ultimately contributing to a more effective and enjoyable leadership development process.

Dee Agarwal posits that virtual reality (VR) simulations can be effective at integrating gamification into leadership development programs. “Virtual reality allows our executives to step into different scenarios, experiencing the challenges and decisions they may face in their roles. This hands-on approach enhances decision-making skills and builds confidence,” explained Agarwal. VR simulations provide a safe space for leaders to test their strategies and learn from the outcomes, contributing to their overall leadership competence.

4. AI-Powered Feedback Systems:

Dee Agarwal underscores the pivotal role of real time feedback in leadership development, emphasizing the significance of AI-powered systems in delivering immediate insights into leadership behaviors. The integration of artificial intelligence allows for an objective analysis of leadership interactions, free from subjective biases that can be present in traditional feedback methods. This objectivity enhances the credibility of the feedback, offering leaders a more accurate portrayal of their strengths and areas for improvement. ”AI enables the generation of personalized feedback, tailoring insights to the specific characteristics and styles of individual leaders,” explained Dee Agarwal. “This personalized approach ensures that the feedback is highly relevant and actionable, allowing leaders to focus on specific aspects that require attention.

The instant feedback loop facilitated by AI is also a key advantage, as it empowers leaders to receive insights promptly after each leadership interaction. This immediacy accelerates the learning process, enabling leaders to reflect on and apply lessons in real-time. Beyond just immediate insights, AI supports a continuous improvement cycle by monitoring and analyzing leadership behaviors over time. Leaders can track their progress, identify trends, and make iterative adjustments, aligning with the principles of agile leadership development. Dee Agarwal adds, “The data-driven nature of AI contributes to informed decision-making, as leaders can strategically prioritize development areas based on evidence-supported insights.”

5. E-Learning Modules for Continuous Development:

In the pursuit of continuous development, Dee Agarwal also employs e-learning modules for leaders. He stated, “Leadership development is an ongoing journey, not a one-time event. E-learning modules provide our leaders with on-demand access to valuable resources, allowing them to stay updated on industry trends and leadership best practices.” This digital approach ensures that leaders within the organization can adapt to evolving challenges and stay ahead in their leadership roles.

6. Virtual Reality Leadership Simulations:

To elevate the learning experience, Agarwal posits integrating virtual reality (VR) simulations into leadership development programs. “Virtual reality allows our executives to step into different scenarios, experiencing the challenges and decisions they may face in their roles. This hands-on approach enhances decision-making skills and builds confidence,” explained Agarwal. VR simulations provide a safe space for leaders to test their strategies and learn from the outcomes, contributing to their overall leadership competence.

7. Social Learning Platforms:

Harnessing the power of social learning, Dee Agarwal incorporates platforms that facilitate collaborative learning among leaders. “Leadership is not a solitary journey; it thrives in a community. Social learning platforms create spaces for leaders to share experiences, exchange insights, and build a supportive network,” Agarwal noted. By fostering a sense of community, these platforms contribute to the development of well-rounded leaders who can thrive in diverse and dynamic environments.

Dee Agarwal’s digital approaches to leadership development underscore the transformative power of technology in shaping effective leaders. From virtual workshops to AI-powered feedback systems and virtual reality simulations, these methods create a holistic and adaptive learning environment. As technology continues to evolve, so too will the landscape of leadership development, guided by forward-thinking leaders like Dee Agarwal.

Media Contact
Company Name: Cambridge Global
Contact Person: Andrew Mitchell
Email: Send Email
Phone: 404-955-7133
City: Atlanta
State: Georgia
Country: United States
Website: https://deeagarwal.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Leveraging Technology for Leadership Development: Dee Agarwal\’s Digital Approaches